Meta Manus Acquisition Blocked by China

Meta Manus acquisition blocked by China's NDRC on April 27, 2026, raising policy risk for cross-border AI deals and pressuring Meta's deal flow.

April 27, 2026·2 min read
View all news articles
Flat vector of a server module with a fractured shell representing Meta Manus acquisition blocked and tighter AI controls

KEY TAKEAWAYS

  • NDRC ordered revocation of Meta's Manus acquisition on April 27, 2026, citing national-security and export-control concerns.
  • Deal announced December 2025 and valued at about $2.0 billion; Manus exceeded $100 million annualized revenue.
  • NDRC directed domestic AI firms to reject U.S. capital and prompted a U.S. Treasury review.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Meta Platforms Inc.'s planned acquisition of Manus was blocked on April 27, 2026, when China’s National Development and Reform Commission (NDRC) ordered the transaction revoked, citing national-security and export-control concerns. The decision halted a months-long cross-border purchase.

China Orders Revocation of Manus Deal

The NDRC prohibited Meta’s acquisition of Manus after a months-long investigation by China’s Ministry of Commerce into export controls and foreign-investment compliance. The Office of the Working Mechanism for Foreign Investment Security Review enforced the revocation, reflecting Beijing’s tighter controls on foreign investment in sensitive AI technologies.

In addition, the NDRC directed several domestic AI companies, including Moonshot AI, Stepfun, and ByteDance, to reject U.S. capital without prior approval. U.S. officials opened a Treasury Department review of the transaction under sensitive technology investment rules, though no U.S. regulatory block has been reported.

Manus and Deal Details

Meta announced the approximately $2 billion acquisition in December 2025 to accelerate its agentic artificial intelligence (AI) capabilities. Manus, a Singapore-registered startup with Chinese founders and roots, launched in March 2025 and had surpassed $100 million in annualized revenue by the end of that year.

Manus’s co-founders, CEO Xiao Hong and Chief Scientific Officer Ji Yichao, were summoned to meetings in March 2026 and barred from leaving China as authorities reviewed the transaction and related technology transfers.

The NDRC’s order and related directives signal a tightening of rules on cross-border investment in advanced AI and highlight growing scrutiny of technology transfers between Beijing and Washington. This development will likely influence future dealmaking in the sector.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Sun Pharma to Acquire Organon

Sun Pharma to Acquire Organon

Sun Pharma to Acquire Organon. Sun agreed April 26, 2026 to buy Organon for $14 a share and an $11.8 billion EV, raising leverage and closing timing risk.

Apple CEO John Ternus Faces Siri and Talent Tests

Apple CEO John Ternus Faces Siri and Talent Tests

Apple CEO John Ternus faces an early iPhone launch and a Siri overhaul that traders will watch for signals on product cadence and talent risk.

Charter Q1 2026 Results Signal Weak Broadband

Charter Q1 2026 Results Signal Weak Broadband

Charter Q1 2026 results show revenue decline and larger-than-expected broadband losses that produced an EPS miss and complicate capital plans.

Google to Invest in Anthropic in Up to $40B Deal

Google to Invest in Anthropic in Up to $40B Deal

Google to Invest in Anthropic reshapes private AI valuations and cloud ties; a $10B initial and up-to-$40B pledge alters private-market pricing.

X-Energy IPO Debuts on Nasdaq

X-Energy IPO Debuts on Nasdaq

X-Energy IPO set a strong Nasdaq open after an upsized, heavily subscribed offering, boosting early valuation and concentrating near-term trader flows.

Regeneron MFN Deal Lowers Prices, Offers Free Gene Therapy

Regeneron MFN Deal Lowers Prices, Offers Free Gene Therapy

Regeneron MFN deal cuts U.S. drug prices and offers Otarmeni free while securing tariff relief, and may push investors to reprice launch economics.